Information about this project is available on our data partner’s website: New Brunswick Institute for Research, Data and Training (NB-IRDT) at the University of New Brunswick.
Real-world evaluation of pertuzumab+trastuzumab compared to trastuzumab+chemotherapy backbone for first-line treatment of patients with HER-2 positive unresectable locally recurrent or metastatic breast cancer
- Lead/Principal Investigator: Ted McDonald
- Status: Complete
- Year Started: 2020
- Location: Fredericton, New Brunswick
- Year Completed: 2022
- Project Number: P0056
- Health Priority: Chronic disease prevention and management